The U.S. Food and Drug Administration (FDA) has approved Otarmeni, a groundbreaking gene therapy developed by Regeneron, marking the first treatment of its kind for inherited deafness caused by mutations in the OTOF gene. This one-time treatment utilizes harmless viruses to deliver functional copies of the OTOF gene into the inner ear, crucial for translating vibrations into brain signals. In a trial involving 20 participants, 16 demonstrated improved hearing within six months, and one additional participant showed improvement within a year, with some achieving hearing levels that negate the need for cochlear implants. Regeneron announced the therapy's approval for both children and adults with OTOF-related hearing loss on Thursday, April 23.